SCHEMBL667271

SCHEMBL667271

CCNS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.65
CA2 P00918 4/20 0.65
CA12 O43570 1/20 0.65
CA3 P07451 1/20 0.65
CA4 P22748 1/20 0.65
CA6 P23280 1/20 0.65
CA5A P35218 1/20 0.65
CA7 P43166 1/20 0.65
CA9 Q16790 1/20 0.65
CA13 Q8N1Q1 1/20 0.65
CA14 Q9ULX7 1/20 0.65
CA5B Q9Y2D0 1/20 0.65
ALDH1A1 P00352 3/20 0.61
CYP19A1 P11511 1/20 0.59
MMP1 P03956 1/20 0.59
MMP2 P08253 1/20 0.59
MMP9 P14780 1/20 0.59
MMP8 P22894 1/20 0.59
MMP13 P45452 1/20 0.59
VCAM1 P19320 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diethylamine SCHEMBL4006972 0.95 CA1 (0.59) CA1CA2CA12CA3CA4
SCHEMBL3685056 0.86 MEN1 (0.62) CA1CA2CA12CA3CA4
SCHEMBL7526085 0.85 CA2 (0.63) CA1CA2CA12CA3CA4
SCHEMBL11511836 0.84 ALDH1A1 (0.83) CA1CA2CA12CA9ALDH1A1
SCHEMBL4091384 0.83 ALDH1A1 (0.64) CA1CA2CA12CA3CA4
SCHEMBL28928577 0.82 CA2 (0.61) CA1CA2CA12CA3CA4
SCHEMBL922441 0.82 KMT2A (0.77) CA1CA2CA5AALDH1A1CYP19A1
SCHEMBL6302342 0.81 CYP19A1 (0.59) CA1CA2CA12CA3CA4
SCHEMBL2624208 0.81 CA2 (0.59) CA1CA2CA12CA3CA4
SCHEMBL10644344 0.81 CA2 (0.59) CA1CA2CA12CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108117499-B Preparation method of alpha aryl amidine imine derivative 上海应用技术大学 2020-10-09 CN claimed
CN-108117499-A A kind of preparation method of α aryl amidine imine derivative 上海应用技术大学 2018-06-05 CN claimed
EP-4719413-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF Animol Discovery, Inc. (US) 2026-04-08 EP disclosed
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY INC (US) 2026-04-02 US disclosed
WO-2024246837-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY, INC. (US) 2024-12-05 WO disclosed
CN-108117499-A A kind of preparation method of α aryl amidine imine derivative 上海应用技术大学 2018-06-05 CN disclosed
CN-102317269-B Novel amino aza heterocyclic carboxamides MERCK PATENT GMBH 2015-06-17 CN disclosed
EP-2396307-B1 NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES MERCK PATENT GMBH (DE) 2014-10-15 EP disclosed
US-20140107156-A1 Novel Amino Azaheterocyclic Carboxamides MERCK PATENT GMBH (DE) 2014-04-17 US disclosed
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US disclosed
US-8637532-B2 Amino azaheterocyclic carboxamides MERCK PATENT GMBH (DE) 2014-01-28 US disclosed
WO-2010093419-A1 NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES MERCK PATENT GMBH (DE) 2010-08-19 WO disclosed
US-20090076287-A1 METHOD OF OBTAINING DERIVATIVES OF 4-(N-ALKYLAMINE)-5,6-DIHYDRO-4H-THIENO-[2,3-B]-THIOPYRAN RAGACTIVES, S.L. (ES) 2009-03-19 US disclosed
EP-1813618-A1 METHOD OF OBTAINING DERIVATIVES OF 4-(N-ALKYLAMINE)-5,6-DIHYDRO-4H-THIENO-[2,3-B]-THIOPYRAN Ragactives, S.L. (ES) 2007-08-01 EP disclosed
US-7105503-B2 Pyrazole compounds QLT INC. (CA) 2006-09-12 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed
CN-1671379-A Hydrazinopyrazole derivatives and their use as therapeutic agents QUADRA LOGIC TECH INC (CA) 2005-09-21 CN disclosed
EP-1450791-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Kinetek Pharmaceuticals, Inc. (CA) 2004-09-01 EP disclosed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 WO disclosed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076287-A1 METHOD OF OBTAINING DERIVATIVES OF 4-(N-ALKYLAMINE)-5,6-DIHYDRO-4H-THIENO-[2,3-B]-THIOPYRAN DTYMK, NT5C, ALKBH5 CA1 4150/4885CA2 2723/4885CA12 3579/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 CA1 4214/4885CA2 1604/4885CA12 3989/4885
US-20140107156-A1 Novel Amino Azaheterocyclic Carboxamides AZI2, MKI67, MYC CA1 4422/4885CA2 3469/4885CA12 2390/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC CA1 4303/4885CA2 2257/4885CA12 3071/4885
US-20030060453-A1 Pyrazole compounds CCNC, MKI67, CDC25C CA1 4672/4885CA2 2665/4885CA12 4673/4885
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF JAK1, JAK3, JAK2 CA1 2926/4885CA2 1072/4885CA12 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.